New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
10:01 EDTSQBK, TWOU, ATEN, AGTC, AHP, NAVIV, ATO, PCRX, SLMVVOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 2U (TWOU) initiated with a Buy at Compass Point... A10 Networks (ATEN) initiated with a Buy at Citigroup... Applied Genetic (AGTC) initiated with a Buy at Cantor... Ashford Hospitality Prime (AHP) initiated with a Hold at Deutsche Bank... Atmos Energy (ATO) initiated with a Neutral at JPMorgan... Navient (NAVIV) initiated with a Buy at Goldman... Pacira Pharmaceuticals (PCRX) initiated with a Buy at BofA/Merrill... Puma Biotechnology (PBYI) initiated with a Buy at Citigroup... Sallie Mae Bank (SLMVV) initiated with a Neutral at Goldman... Square 1 Financial (SQBK) initiated with a Market Perform at Keefe Bruyette.
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
17:21 EDTATENA10 Networks sees Q4 EPS (20c)-(13c), consensus (11c)
Aten sees Q4 revenue $41M-$45M, consensus $47.23M. Guidance provided on earnings conference call.
16:58 EDTAHPAshford Hospitality Prime reports Q3 EPS 13c, consensus 10c
Subscribe for More Information
16:22 EDTATENA10 Networks reports Q3 EPS (15c), consensus (12c)
Reports Q3 revenue $43.4M, consensus $43.24M.
13:12 EDTPCRXPacira weakness a buying opportunity, says Brean Capital
Brean Capital believes the weakness in shares of Pacira following its Q3 report is a buying opportunity, noting that the company hit the consensus for revenue despite a lower number of orthopedic surgeries, which the firm views as seasonally impacted. Brean also noted Pacira said it has seen no change in surgeons’ perception of Exparel following the FDA warning letter it received in September. The firm maintains its Buy rating and $111 price target on the stock.
10:55 EDTPCRXPacira shares defended at Wedbush
Subscribe for More Information
09:14 EDTPCRXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Visa (V), up 4%... MasterCard (MA), up 2.5%... Alcatel-Lucent (ALU), up 12.5%... TASER (TASR), up 4%... JDSU (JDSU), up 3.8%... Radian Group (RDN), up 9%... DreamWorks Animation (DWA), up 1.7%... Take-Two (TTWO), up 7.7%. ALSO HIGHER: Grand Canyon (LOPE), up 10.5%, upgraded at Piper Jaffray after the company formed a committee to explore conversion to a nonprofit entity... Walter Energy (WLT), up 6.8% after lowering FY14 capital expenditures view, reporting lower than expected losses... Novavax (NVAX), up 7% after getting fast track designation for H7N9 VLP. DOWN AFTER EARNINGS: Glu Mobile (GLUU), down 16.6%... Alliance Fiber Optic (AFOP), down 18.4%... Pacira (PCRX), down 6.4%. ALSO LOWER: Sturm, Ruger (RGR), down 10% following Q3 results, cutting Q3 dividend. Peer gunmaker Smith & Wesson (SWHC) also down 3.7% after Ruger's report... Western Gas Partners (WES), down 4.4% after its 7.5M common units spot secondary priced at $70.85... ACCO Brands (ACCO), down 1.1%, downgraded at KeyBanc following the company's Q3 results... Fiat Chrysler (FCAU), down 1.1% after reported to be recalling over 300K Ram trucks due to fire concern... Inogen (INGN), down 2.3% after 2.1M share secondary offering of common stock priced at $21.50.
06:32 EDTPCRXPacira reports Q3 Exparel net product sales up 12% to $50.2M
Subscribe for More Information
06:31 EDTPCRXPacira reports Q3 non-GAAP EPS 16c, consensus 10c
Subscribe for More Information
October 27, 2014
16:03 EDTPCRXPacira EXPAREL use leads to significant reduction in opioid adverse events
Pacira Pharmaceuticals announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complications associated with opioid use. The data, presented at the American College of Surgeons, or ACS, Clinical Congress, found that patients treated with EXPAREL experienced statistically significantly lower rates of urinary retention, respiratory depression and fall risk compared to their counterparts who received the previous standard of care, or SOC. The ACS Clinical Congress is being held October 26-30 at the Moscone Center in San Francisco. The study evaluated 82 patients undergoing open ventral hernia repair or laparoscopic colon resection, all of whom were treated by Dr. Redan. Thirty-seven patients received the SOC: intravenous hydromorphone or morphine with or without epidurals and/or IV acetaminophen. The other 45 patients received infiltration with EXPAREL in addition to the SOC. of EXPAREL resulted in a statistically significant reduction (P<0.001) in the amount of patients classified as being “high-risk” for falls (8.4% in the EXPAREL group vs 16% in the SOC group) and an increase in patients classified as being “low-risk” for falls (48.7% in the EXPAREL vs 37.6% in the SOC group), according to the Morse Fall Scale designed to predict falls, and assess and address risk factors contributing to fall risk.
07:23 EDTPCRXAmerican College of Surgeons holds a conference
Subscribe for More Information
06:12 EDTAHPAshford Hospitality Prime announces $100M share repurchase program
Ashford Hospitality Prime announced that its board has approved a share repurchase program for the company to purchase up to $100M of the company's common stock. The repurchase program is anticipated to commence two business days after the company reports Q3 earnings, which is scheduled for Thursday, October 30. The company also announced that it will look to sell the Courtyard Downtown Philadelphia and potentially other hotels in the Ashford Prime portfolio with the intention to use the net proceeds to fund the share repurchase program.
October 24, 2014
07:50 EDTATENA10 Networks price target lowered to $6 from $16 at RBC Capital
Subscribe for More Information
October 23, 2014
07:08 EDTSQBKSquare 1 Financial reports Q3 EPS 29c, consensus 23c
Subscribe for More Information
October 20, 2014
07:12 EDTPCRXCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
October 17, 2014
06:30 EDTATOAtmos Energy upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Atmos Energy to Overweight saying the recent pullback in shares provides a compelling entry point. The firm raised its price target for the stock to $57 from $52.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use